Boehringer Ingelheim Reports Strong Growth in 2023 and Accelerates Late-stage Pipeline
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV® Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launches R&D expenditures increase by 14.2% to EUR 5.8 bn Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key [...]